Healthcare Services

A key trend shaping the Oral Mucositis Market involves the Advancements In Cryotherapy For Managing Chemotherapy Side Effect

April 3, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Oral Mucositis Market Between 2026 And 2030?

The oral mucositis market has seen significant expansion in recent years. It is forecast to expand from $1.55 billion in 2025 to $1.67 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.6%. The historical growth can be attributed to the rising application of high-dose chemotherapy regimens, an increasing occurrence of head and neck cancers, the growing volume of hematopoietic stem cell transplant procedures, the constrained availability of effective preventive therapies, and escalating hospitalization rates for complications arising from cancer treatment.

The oral mucositis market size is anticipated to experience substantial expansion in the coming years. This market is projected to reach $2.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.3%. The expansion during this forecast period stems from factors such as increased investment in oncology supportive care research, a rise in approvals for innovative mucositis therapeutics, heightened awareness regarding the early diagnosis and management of oral mucositis, the expansion of oncology treatment infrastructure within developing markets, and a growing emphasis on patient-centric cancer care strategies. Key trends for the forecast period encompass a rising occurrence of oral mucositis induced by chemotherapy and radiotherapy, increased uptake of targeted and biologic therapies for managing mucositis, an escalating focus on preventive oral care protocols in oncology environments, a growing need for liquid and easily administrable dosage forms, and a heightened clinical emphasis on enhancing the quality of life for cancer patients.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21237&type=smp

What Key Drivers Are Influencing The Growth Of The Oral Mucositis Market?

The expanding occurrence of cancer is projected to fuel the expansion of the oral mucositis market moving ahead. Cancer is a condition defined by the unrestrained proliferation and dissemination of atypical cells within the body, capable of infiltrating and devastating healthy tissues. The rising incidence of cancer cases stems from elements like an aging demographic, shifts in lifestyle, exposure to environmental factors, infections, and genetic susceptibility. Therapy for oral mucositis assists cancer patients by easing discomfort, diminishing inflammation, averting subsequent infections, and fostering quicker recovery of oral tissues, thereby enhancing their well-being, nutrient consumption, and general quality of life throughout chemotherapy or radiation treatments. As an illustration, in May 2024, the National Cancer Institute, a US-based government agency, stated that globally, around 20 million new cancer cases and 9.7 million cancer-related fatalities were documented in 2022. Forecasts indicate these figures might rise to 29.9 million new cases and 15.3 million deaths per year by 2040. Consequently, the growing occurrence of cancer is propelling the development of the oral mucositis market.

Which Market Segments Are Examined In The Oral Mucositis Market Study?

The oral mucositis market covered in this report is segmented –

1) By Indication: Chemotherapy, Radiotherapy, Hematopoietic Stem Cell Transplantation

2) By Product Type: Solid Dosage Form, Liquid Dosage Form

3) By Treatment: Palifermin, Amifostine, Chlorhexidine, Sucralfate, Avasopasem, Dusquetide

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Dental Clinics, Oncology Hospitals, Research Institutes

Subsegments:

1) By Chemotherapy: High-Dose Chemotherapy-Induced Oral Mucositis, Standard-Dose Chemotherapy-Induced Oral Mucositis

2) By Radiotherapy: Head And Neck Cancer Radiotherapy-Induced Oral Mucositis, Total Body Irradiation-Induced Oral Mucositis

3) By Hematopoietic Stem Cell Transplantation: Autologous Stem Cell Transplantation-Induced Oral Mucositis, Allogeneic Stem Cell Transplantation-Induced Oral Mucositis

What Major Market Trends Are Driving Changes In The Oral Mucositis Market?

Leading companies within the oral mucositis market are concentrating on developing innovative solutions, such as cryotherapy, to diminish the severity and occurrence of the condition by employing cold therapy to safeguard oral tissues. Cryotherapy itself is a medical procedure that utilizes extreme cold to freeze and eliminate abnormal or diseased tissue, typically used for ailments like warts, tumors, or injuries. For instance, in February 2024, Chemo Mouthpiece LLC, a US-based medical device company, announced that its chemo mouthpiece device had received approval from the Food and Drug Administration, a US-based government agency. This chemo mouthpiece acts as an intraoral ice pack that delivers cryotherapy to the oral cavity of patients undergoing chemotherapy, proactively managing and treating oral mucositis, which is a common and painful side effect of chemotherapy.

Who Are The Primary Competitors In The Oral Mucositis Market?

Major companies operating in the oral mucositis market are Mundipharma International Limited, EUSA Pharma, Galera Therapeutics Inc., Enzychem Lifesciences Corporation, Oragenics Inc., Soligenix Inc., Monopar Therapeutics Inc., EpicentRx, Cellceutix Corporation, GlycoMira Therapeutics Inc., Solasia Pharma KK, 3M Healthcare, GlaxoSmithKline plc, Pfizer Inc., Colgate-Palmolive Company, CANbridge Pharmaceuticals Inc., Helsinn Healthcare SA, Camurus AB, Norgine B.V., Clinigen Group plc, Alliance Pharma plc, Amag Pharmaceuticals, Izun Pharmaceuticals Corporation, Spherium Biomed, Mission Pharmacal, Access Pharmaceuticals Inc., Otsuka Pharmaceuticals

Read the full oral mucositis market report here:

https://www.thebusinessresearchcompany.com/report/oral-mucositis-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Oral Mucositis Market?

North America was the largest region in the oral mucositis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral mucositis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oral Mucositis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21237&type=smp

Browse Through More Reports Similar to the Global Oral Mucositis Market 2026, By The Business Research Company

Oral Care Global Market Report

https://www.thebusinessresearchcompany.com/report/oral-care-global-market-report

Personal Hygiene Global Market Report

https://www.thebusinessresearchcompany.com/report/personal-hygiene-global-market-report

Mouthwash Global Market Report

https://www.thebusinessresearchcompany.com/report/mouthwash-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795